A multicenter clinical, open-label total dose-escalating phase II study with safety run-in to
explore the clinical activity, total dosage, and safety of daratumumab in adult ITP patients
who have not responded adequately or relapsed after corticosteroids and at least one
second-line therapy including rituximab and/or TPO-RA.
Phase:
Phase 2
Details
Lead Sponsor:
Ostfold Hospital Trust
Collaborators:
Haukeland University Hospital Henri Mondor University Hospital Odense University Hospital Oslo University Hospital University Hospital, Akershus